Skip to main content
. 2023 Jun 28;63(2):65–72. doi: 10.3960/jslrt.23010

Fig. 3.

Fig. 3

GCs variably involved by ISFN. (A) Hematoxylin and eosin staining demonstrates reactive-looking GCs. (B and C) Immunohistochemistry for BCL2 highlights a clear ISFN lesion (*) and GCs with scattered ISFN cells strongly expressing BCL2 (arrow and arrowhead). Note that the number of BCL2-positive cells in GCs are variable as indicated by the arrow and arrowhead.